prasugrel / Generic mfg. - LARVOL DELTA

Efficacy and Safety of a CasRm-Based Therapy for Parkinson's disease in Non-Human Primates (ASGCT 2025) - "Here we present the initial preclinical results of RM-201, an innovative adeno-associated virus (AAV) gene therapy that harnesses a state-of-the-art CasRm system to specifically knock down PTBP1 and high-effiently induce glial-to-neuron transdifferentiation... Our study affirms RM-201 as an efficacious agent for promoting neuronal regeneration and restoring motor abilities in PD NHPs, while maintaining an acceptable safety profile at therapeutic doses. This research provides robust evidence in support of RM-201 as a promising gene editing therapeutic candidate for the treatment of PD patients. Disease Focus of Abstract:Parkinson's Disease"

Clinical • CNS Disorders • Gene Therapies • Movement Disorders • Parkinson's Disease • CASR • NEUROD1 • PTBP1

Discovery of hypoglycemic and cardiovascular drugs as the effective inhibitors on human pancreatic lipase. (PubMed, Chem Biodivers) - "Among them, ticagrelor (HC-14), prasugrel (HC-18), amlodipine (HC-26), simvastatin (HC-32), and lovastatin (HC-33) had strong inhibitory activity against hPL...Further studies showed that HC-14 significantly inhibited hPL activity in AR42J cells, resulting in dose-dependent inhibition. Overall, the above results suggest that ticagrelor is a cardiovascular drug that inhibits hPL, which also provides an important reference for the search and development of other drugs for the treatment of obesity."

Journal • Cardiovascular • Diabetes • Dyslipidemia • Genetic Disorders • Hypertension • Metabolic Disorders • Obesity

Risk of Complications Following Medialization Thyroplasty in Patients on Anticoagulation (COSM 2025) - "Patients taking AC/AP (aspirin, warfarin, apixaban, edoxaban, rivaroxaban, dabigatran, dipyridamole, ticagrelor, prasugrel, clopidogrel, cilostazol, dalteparin, enoxaparin) within 1 month of the procedure were identified and compared to those not taking these medications. Based on analysis of a large healthcare database, MT performed on AC/AP is associated with higher rates of post-operative dysphagia and airway compromise but not postoperative hemorrhage/hematoma."

Clinical • Gastrointestinal Disorder • Hematological Disorders • Infectious Disease

Comparison of Dual Antiplatelet Therapy De-escalation by Dose Reduction Versus Switching in Patients Undergoing PCI: The Switching Antiplatelet-8 (SWAP-8) Study (clinicaltrials.gov) - P4 | N=78 | Recruiting | Sponsor: University of Florida | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Coronary Artery Disease

Exploring the relationship of platelet aggregation function with efficacy and safety outcomes following the administration of prasugrel and clopidogrel in patients with thrombotic stroke: a post hoc analysis of PRASTRO pooled studies. (PubMed, J Thromb Thrombolysis) - "PRU values at 4 and 24 weeks were numerically lower with prasugrel and unaffected by CYP2C19 genetic polymorphisms. Further research is needed to clarify the relationship of PRU with ischemic and bleeding events."

Journal • Retrospective data • Atherosclerosis • Cardiovascular • Ischemic stroke • CYP2C19

Platelet Sub-study of the Neomindset Trial (clinicaltrials.gov) - P4 | N=48 | Active, not recruiting | Sponsor: Hospital Israelita Albert Einstein | Recruiting ➔ Active, not recruiting | Trial completion date: Mar 2024 ➔ Jun 2025 | Trial primary completion date: Feb 2024 ➔ May 2025

Enrollment closed • Monotherapy • Trial completion date • Trial primary completion date • Acute Coronary Syndrome • Cardiovascular

Mesoporous Silica Nanotraps for Mitigating Bleeding Risk From 'Irreversible' Antiplatelet Drugs. (PubMed, Adv Mater) - "Despite the widespread use of clopidogrel and prasugrel for their potent antiplatelet activity, the absence of specific and effective reversal agents remains a notable challenge. Taking advantage of this action mechanism of these "irreversible" antiplatelet drugs, click chemistry-functionalized mesoporous silica (SiO2-Mal) nanotraps are fabricated to capture the antiplatelet drugs' active metabolites and restore hemostasis. Subsequently, a comprehensive assessment of the effectiveness and safety of the SiO2-Mal nanotraps is conducted using mouse, rabbit, and pig animal models, highlighting their potential application as a functional reversal agent for clinically relevant thienopyridine antiplatelet drugs, believed until now to be irreversible in their inhibition of platelet activity."

Journal • Cardiovascular • Hematological Disorders • Thrombosis

NEOMINDSET: Percutaneous Coronary Intervention Followed by Antiplatelet Monotherapy in the Setting of Acute Coronary Syndromes (clinicaltrials.gov) - P3 | N=3400 | Active, not recruiting | Sponsor: Hospital Israelita Albert Einstein | Recruiting ➔ Active, not recruiting | Trial completion date: Jan 2024 ➔ Jun 2025 | Trial primary completion date: Jan 2024 ➔ May 2025

Enrollment closed • Monotherapy • Trial completion date • Trial primary completion date • Acute Coronary Syndrome • Cardiovascular

Prasugrel Monotherapy Reduced Dose in Acute and Chronic Coronary Syndrome Patients After Percutaneous Coronary Intervention (PROMOTE) (clinicaltrials.gov) - P4 | N=300 | Not yet recruiting | Sponsor: J.P.S Henriques

Monotherapy • New P4 trial • Cardiovascular • Coronary Artery Disease

THE EFFECT OF INSURANCE TYPE ON THE SELECTION OF ANTIPLATELET THERAPY AFTER PERCUTANEOUS CORONARY INTERVENTION - Surik Sedrakyan (ACC 2025) - "Background: Ticagrelor and prasugrel have been shown to reduce major adverse cardiac events after percutaneous coronary intervention, with current guidelines recommending their use over clopidogrel. Patients with government-sponsored insurance were more likely to be prescribed clopidogrel, even after adjusting for patient differences. This reflects potential barriers to accessing preferred therapies and raises concerns about disparities in patient care."

Reimbursement • US reimbursement

Debate: Ticagrelor or Prasugrel Are Equally Efficacious in STEMI Patients Undergoing PCI - Luis Ortega Paz (ACC 2025) - No abstract available

Clinical

Debate: Prasugrel Should Be the P2Y12 Agent of Choice in STEMI Patients Undergoing Primary PCI - Adnan Kastrati (ACC 2025) - No abstract available

Clinical

PLATELET AGGREGOMETRY GUIDANCE FOR RECTAL P2Y12 INHIBITION ADMINISTRATION FOLLOWING ACUTE MYOCARDIAL INFARCTION - A CASE SERIES - Kathryn Cox (ACC 2025) - "In this series, pharmacy-compounded rectal slurries were used for essential antiplatelet delivery post-MI. Platelet aggregometry was used to monitor platelet reactivity and the ADP response was effective for both clopidogrel and prasugrel. This team approach to choose the rectal P2Y12 inhibition strategy resulted in no bleeding or ischemic complications for either patient."

Clinical • Acute Coronary Syndrome • Barrett Esophagus • Cardiovascular • Gastrointestinal Disorder • Hematological Disorders • Myocardial Infarction • Respiratory Diseases • Thrombosis

A GENETIC TWIST: JANUS KINASE 2 MUTATION AND ITS CORRELATION WITH ACUTE MYOCARDIAL INFARCTION - Akanksha Maurya (ACC 2025) - "This case report presents a unique scenario where a JAK2 mutation is identified as a potential underlying cause for acute coronary syndrome (ACS).Case: A 37-year-old male with a history of JAK2 mutation, coronary artery disease with left anterior descending (LAD) stent 10 months prior, and portal vein thrombosis on apixaban presented with an acute episode of left-sided chest pain radiating to the neck...His P2Y12 levels were within therapeutic range, however, given thrombosis despite clopidogrel therapy it was switched to prasugrel... JAK2 mutations, although rare, can be associated with acute myocardial infarctions. Hence, it's essential to consider genetic factors in the evaluation of acute coronary syndromes. In depth research is warranted to explore the implications of JAK2 mutations in ACS pathology and its management."

Acute Coronary Syndrome • Cardiovascular • Coronary Artery Disease • Hematological Disorders • Immunology • Inflammatory Arthritis • Myeloproliferative Neoplasm • Myocardial Infarction • Oncology • Pain • Thrombosis • JAK2

BALANCING DRUG-DRUG INTERACTIONS: ASSESSING ANTIPLATELET AND ANTIRETROVIRAL THERAPY IN PEOPLE LIVING WITH HIV - Tania Ahuja (ACC 2025) - "Of these, 119 (80%) were initiated on clopidogrel, 23 (15%) on ticagrelor, and 7 (5%) on prasugrel. We observed a high incidence of DDI between P2Y12inh and ART in PLWH, most commonly with clopidogrel. However, MACE and bleeding events at 1 year did not correlate with expected DDI, therefore it remains unknown if DDI presence at the time of P2Y12 inhibitor initiation with ART is causative for clinical outcomes of concern, or if underlying platelet reactivity in PLWH is associated with these events."

Cardiovascular • Hematological Disorders • Human Immunodeficiency Virus • Infectious Disease • Thrombosis

COMPARING 1-YEAR OUTCOMES OF PRASUGREL VERSUS CLOPIDOGREL IN DUAL ANTIPLATELET THERAPY FOLLOWING PERCUTANEOUS CORONARY INTERVENTION FOR ACUTE CORONARY SYNDROME - Jia Yean Thong (ACC 2025) - "Prasugrel, as part of DAPT after PCI for ACS in a real-world multinational cohort is associated with significantly reduced risks of all-cause mortality, cardiovascular adverse events, and major bleeding over a 1-year follow-up period."

Acute Coronary Syndrome • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Congestive Heart Failure • Gastrointestinal Disorder • Heart Failure • Hematological Disorders • Idiopathic Arthritis • Myocardial Infarction

A NOVEL SYNTHETIC SHORT-CHAIN POLYPHOSPHATE (POLYP) COMPLEXED WITH SILICA NANOPARTICLE (SNP), BYPASSES CANGRELOR-INDUCED P2Y12 INHIBITION AND REDUCES BLOOD LOSS IN A RAT TAIL TRANSECTION MODEL - Damien Kudela (ACC 2025) - "Background: Antiplatelet therapies, such as P2Y12 receptor antagonists (including clopidogel, ticagrelor, prasugrel and cangrelor) play an essential role in prevention of cardiovascular events used alone or in combination with aspirin or oral anticoagulant. These results demonstrate that IV-administered CAY001 could bypass P2Y12 inhibitor (cangrelor)-induced excessive bleeding and blood loss in the rat injury model. CAY001 has the potential as a pro-hemostatic therapeutic for serious or life-threatening bleeding in patients taking an antiplatelet inhibitor and/or anticoagulant."

Preclinical • Anesthesia • Cardiovascular • Thrombosis

COMPARING POST-PCI PRESCRIPTION PATTERNS IN SOUTH ASIAN AND WHITE PATIENTS - Abhinav R. Thummala (ACC 2025) - "Clopidogrel, ticagrelor, and prasugrel were prescribed to 58.2%, 28.6%, and 2.0% of South Asians respectively versus 64.1%, 26.8%, and 1.6% of white patients (p=0.24, 0.70, 0.19 respectively). In our sample of patients who underwent PCI, South Asians were significantly more likely to receive an ACEi/ARB at discharge. There was a trend towards significance in prescriptions of aspirin and beta-blockers, with South Asians less likely to receive aspirin and more likely to receive a beta-blocker. There was no difference in prescription of P2Y12-inhibitors."

Clinical • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Diabetes • Diabetic Nephropathy • Heart Failure • Metabolic Disorders • Myocardial Infarction • Nephrology • Renal Disease

PREDICTORS AND TEMPORAL TRENDS OF HIGH-POTENCY P2Y12 INHIBITOR USE AFTER PERCUTANEOUS CORONARY INTERVENTION FOR ACUTE CORONARY SYNDROME (ACS): IMPACT OF ISAR-REACT 5 AND 2021 ACC/AHA REVASCULARIZATION GUIDELINES - Binish Qureshi (ACC 2025) - "Background: Societal guidelines recommend high-potency P2Y12 inhibitors (ticagrelor and prasugrel) over clopidogrel after percutaneous coronary intervention (PCI) in patients with acute coronary syndrome (ACS). In this observational analysis from a large international database (predominately US sites) of ACS patients undergoing PCI, clopidogrel remains the most widely prescribed P2Y12 inhibitor. Prasugrel use sharply increased after the publication of the ISAR-REACT 5 study and the 2021 revascularization guidelines."

Acute Coronary Syndrome • Cardiovascular

Elderly patients are hyperresponsive to potent P2Y12 inhibitors. (PubMed, Res Pract Thromb Haemost) - "Platelet aggregation in response to arachidonic acid (AA), ADP, collagen, the protease-activated receptor-1 agonist SFLLRN, and the protease-activated receptor-4 agonist AYPGKF was assessed by multiple electrode aggregometry in 79 prasugrel- and 77 ticagrelor-treated patients 3 days after acute percutaneous coronary intervention. Patients aged ≥70 years on potent P2Y12 inhibitors exhibit increased inhibition of ADP-inducible platelet aggregation. In addition, elderly patients on prasugrel show a lower response to AA, collagen, SFLLRN and AYPGKF than younger patients."

Journal

AZ-DAPT: Disparities in the Proportion of Ticagrelor and Prasugrel-eligible Patients with Acute Coronary Syndrome in a Real-world Registry (clinicaltrials.gov) - P=N/A | N=6789 | Completed | Sponsor: University Hospital Heidelberg | Recruiting ➔ Completed | Trial completion date: Dec 2023 ➔ Dec 2024 | Trial primary completion date: Sep 2023 ➔ Dec 2024

Real-world evidence • Trial completion • Trial completion date • Trial primary completion date • Acute Coronary Syndrome • Cardiovascular • Myocardial Infarction

Treatment outcomes and effectiveness of FRED for fusiform vertebral artery aneurysms. (PubMed, Interv Neuroradiol) - "Patients received 100 mg aspirin and 3.75 mg prasugrel for at least 7 days prior to surgery. In the fusiform group, 18 out of 20 cases (90%) achieved good obliteration, whereas only 2 out of 9 cases (34%) in the saccular group did. Multivariate analysis indicated that fusiform aneurysm type was a significant predictor of good obliteration.ConclusionsThe treatment effect of FRED on the fusiform VA aneurysm appears to differ from the outcomes based on the pipeline device, suggesting the potential for achieving favorable results earlier in fusiform cases."

Journal • Cardiovascular • Diabetes • Dyslipidemia • Hypertension • Metabolic Disorders

Short-term safety study of prasugrel in patients with acute non-cardiac ischemic cerebrovascular disorder (JSNE 2025) - No abstract available

Clinical • CNS Disorders • Myocardial Ischemia • Vascular Neurology

Changes in PRU before and after oral administration of prasugrel in patients with acute cerebral infarction (JSNE 2025) - No abstract available

Clinical • CNS Disorders

Comparison of P2Y12 inhibitors and aspirin in secondary prevention of coronary events: a meta-analysis of RCTs. (PubMed, BMC Cardiovasc Disord) - "Compared with aspirin, P2Y12 inhibitors reduce risk of myocardial infarction and hemorrhagic stroke in the secondary prevention of CAD. However, there is no significant differences in major bleeding or all-cause mortality. Further research, including subgroup analyses and studies in diverse populations, is needed to validate these findings and explore genetic factors that may influence treatment outcomes."

Clinical • Journal • Retrospective data • Review • Cardiovascular • Cerebral Hemorrhage • Coronary Artery Disease • Gastrointestinal Disorder • Heart Failure • Hematological Disorders • Myocardial Infarction